Registration is Open for VVMA Winter 2022 CE Conference

We will be holding a one-day, in-person conference at The DoubleTree by Hilton Hotel in South Burlington, VT on Sunday, February 6, 2022.   Early registration discounts are available until January 24.    The DoubleTree by Hilton has a block of rooms reserved for $129/night plus taxes - this discounted price will expire on January 15, 2022 so reserve early if you plan to stay overnight.  Our Small Animal Program will be on Anesthesia and Pain Management and will be presented by Dr. Manuel Martin-Flores from Cornell University.  Our Large Animal Track will be on Field Surgical Procedures and will be presented by Dr. Andre Desrochers from the University of Montreal.  We will also provide an update on DEA Compliance - 1-hour practice management CE free for conference attendees from 7:45 am-8:45 am.   For more information and for pricing, visit the VVMA Winter Meeting page

Save the Dates !

Due to a recent spike in COVID rates, we made the decision to switch our Winter Meeting over to a 1 day event and the VVMA Summer 2022 will be a 2 day event, in-person at the DoubleTree by Hilton Hotel in South Burlington, VT, June 11 and 12.  Mark your calendars and save the dates  Details to follow.



Xylazine Warning for Vermont’s Veterinarians From VT Dept. of Health

The Health Department recently published a data brief on the emerging trend of xylazine contributing to fatal opioid overdoses based on a CDC Morbidity and Mortality Weekly Report. Vermont’s data brief can be found here: - XylazineBrief.pdf

·       Law enforcement believes that xylazine may be added as a toxic adulterant in illicit opioids in the US, and it is being added before those opioids arrive in Vermont.

·       In the past, trends like this originate in larger urban centers in the Northeast and Mid- Atlantic before they are detected in Vermont; this trend is currently being seen in these urban areas.

·       We request that Vermont’s veterinarians closely monitor their supplies of xylazine for potential diversion, including taking care to not dispense single doses of xylazine for subsequent and unsupervised use.

·       If you suspect drug diversion, please follow your usual notification pathway, which may include law enforcement or the Vermont Office of Professional Regulation.

Please direct any questions about the data brief to the Health Department’s Substance Misuse Prevention Manager, Nicole Rau.